News
Lilly's obesity pill lags Novo's Wegovy injection in key trial
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy.
Lilly's Weight Loss Pill Falls Short of Novo's Wegovy in Key Study
Eli Lilly's GLP-1 pill, orforglipron, led to 12.4% weight loss in a 72-week study, falling short of Novo Nordisk's Wegovy. Despite the results, Lilly plans to seek global approval, highlighting the pill's potential for convenience and its heart health benefits.
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, ...
Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly's experimental GLP-1 pill, orforglipron, helped patients lose 12.4% of their body weight in a late-stage study, ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback